Abolishing Retro-Transduction of Producer Cells in Lentiviral Vector Manufacturing.


Journal

Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722

Informations de publication

Date de publication:
29 Jul 2024
Historique:
received: 26 06 2024
revised: 26 07 2024
accepted: 27 07 2024
medline: 1 9 2024
pubmed: 31 8 2024
entrez: 29 8 2024
Statut: epublish

Résumé

Transduction of producer cells during lentiviral vector (LVV) production causes the loss of 70-90% of viable particles. This process is called retro-transduction and it is a consequence of the interaction between the LVV envelope protein, VSV-G, and the LDL receptor located on the producer cell membrane, allowing lentiviral vector transduction. Avoiding retro-transduction in LVV manufacturing is crucial to improve net production and, therefore, the efficiency of the production process. Here, we describe a method for quantifying the transduction of producer cells and three different strategies that, focused on the interaction between VSV-G and the LDLR, aim to reduce retro-transduction.

Identifiants

pubmed: 39205190
pii: v16081216
doi: 10.3390/v16081216
pii:
doi:

Substances chimiques

Receptors, LDL 0
Viral Envelope Proteins 0
G protein, vesicular stomatitis virus 0
Membrane Glycoproteins 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Subventions

Organisme : Basque Government
ID : ZL-2020/00297
Organisme : Basque Government
ID : ZL-2024/00268
Organisme : Basque Government
ID : 012-B1/2021
Organisme : Ministerio de Ciencia, Innovación y Universidades
ID : PTQ2020-010965

Auteurs

Soledad Banos-Mateos (S)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Carlos Lopez-Robles (C)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

María Eugenia Yubero (ME)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Aroa Jurado (A)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Ane Arbelaiz-Sarasola (A)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Andrés Lamsfus-Calle (A)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Ane Arrasate (A)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Carmen Albo (C)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Juan Carlos Ramírez (JC)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Marie J Fertin (MJ)

VIVEbiotech, Tandem Building, 20014 Donostia, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH